Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug234 | Aerosolized All-Trans Retinoic acid plus oral Tamoxifen Wiki | 1.00 |
| drug3764 | Standard treatment Wiki | 0.38 |
| drug3516 | Saliva collection Wiki | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Prospective, mono centric study on COVID-19 patients with or without acute respiratory distress syndrome (ARDS) to analyse the dynamics of the immune response and to search for biomarkers of evolution
Description: Blood sample
Measure: Number of increased immune population Time: Month 4Description: Blood sample
Measure: Number of decreased immune population Time: Month 4Description: Blood sample
Measure: Number of statically different phenotypes compared to control patients Time: Month 4Description: Qualitative identification of immune subpopulations showing a significant variation compared to controls and quantification of this variation (at D1 and/or D14)
Measure: Gain or loss of functional phenotypic markers between D1 and D14 Time: Day 14Description: Qualitative identification of immune subpopulations showing a significant variation between acute and mild COVID-19 and quantification of this variation (at D1 and/or D14)
Measure: Gain or loss of functional phenotypic markers between between acute and mild infections Time: Day 14Description: Qualitative identification of immune subpopulations showing a significant variation between acute stage and recovery (at 4 months) and quantification of this variation
Measure: Gain or loss of functional phenotypic markers between D1 and month 4 Time: Month 4Description: Blood sample
Measure: Evaluation of V, D, J gene usage alterations in the immunoglobulin and T cell receptor (TCR) repertoires during ARDS linked to COVID-19 Time: Day 14Description: Blood sample
Measure: Identification of the Ig classes and of V, D, J sequences of anti-CoV-2 antibodies Time: Month 4Description: Blood sample
Measure: Characterization of a new set of human antibodies from patients who have recovered of COVID-19 Time: Month 4Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports